Reclassification of medicines: NIQUITIN CQ 4mg LOZENGES and NIQUITIN CQ 4mg MINT LOZENGES

Home > Notice-board > Reclassification > NiQuitin CQ 4mg lozenges and NiQuitin CQ 4mg mint lozenges

NiQuitin CQ 4mg lozenges and NiQuitin CQ 4mg mint lozenges

GlaxoSmithKline Consumer Healthcare has asked the Medicines and Healthcare products Regulatory Agency to reclassify NiQuitin CQ 4mg lozenges and NiQuitin CQ 4mg mint lozenges (4mg nicotine as 22.2mg nicotine polacrilex) as general sale list medicines. Both products are currently pharmacy medicines licensed for the relief of nicotine withdrawal symptoms including cravings associated with smoking cessation.

Consultation period: 10 February 2003 to 24 March 2003.

ARM 6: request to reclassify NiQuitin CQ 4mg lozenges from P to GSL
(Microsoft Word document)

Reclassification
P to GSL

Status
Completed